C Ehmen1, R Medialdea-Carrera2, D Brown3, A M Bispo de Filippis3, P Carvalho de Sequeira3, R M Ribeiro Nogueira3, P Brasil4, G A Calvet4, J Blessmann5, A-M Mallmann1, J Sievertsen1, A Rackow1, J Schmidt-Chanasit6, P Emmerich6,7, H Schmitz6, C Deschermeier1, A Mika1. 1. Diagnostics Development Laboratory, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. 2. Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK. 3. Flavivirus Reference Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. 4. Acute Febrile Illnesses Laboratory, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. 5. Department for Infectious Disease Epidemiology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. 6. Department for Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. 7. Department of Tropical Medicine and Infectious Diseases, Center of Internal Medicine II, University of Rostock, Rostock, Germany.
Abstract
OBJECTIVES: Accurate serological assays are urgently needed to support public health responses to Zika virus (ZIKV) infection with its potential to cause foetal damage during pregnancy. Current flavivirus serology for ZIKV infections lacks specificity due to cross-reacting antibodies from closely related other flaviviruses. In this study, we evaluated novel serological tests for accurate ZIKV IgG detection. METHODS: Our ELISAs are based on immune complex binding. The high specificity is achieved by the simultaneous incubation of labelled ZIKV antigen and unlabelled flavivirus homolog protein competitors. Two assays were validated with a panel of 406 human samples from PCR-confirmed ZIKV patients collected in Brazil (n = 154), healthy blood donors and other infections from Brazil, Europe, Canada and Colombia (n = 252). RESULTS: The highest specificity (100% [252/252, 95% confidence interval (CI) 98.5-100.0]) was shown by the ZIKV ED3 ICB ELISA using the ED3 antigen of the ZIKV envelope. A similar test using the NS1 antigen (ZIKV NS1 ICB ELISA) was slightly less specific (92.1% [232/252, 95% CI 88.0-95.1]). The commercial Euroimmun ZIKV ELISA had a specificity of only 82.1% (207/252, 95% CI 76.8-86.7). Sensitivity was high (93-100%) from day 12 after onset of symptoms in all three tests. Seroprevalence of ZIKV IgG was analysed in 87 samples from Laos (Asia) confirming that the ED3 ELISA showed specific reactions in other populations. CONCLUSIONS: The novel ED3 ICB ELISA will be useful for ZIKV-specific IgG detection for seroepidemiological studies and serological diagnosis for case management in travellers and in countries where other flavivirus infections are co-circulating.
OBJECTIVES: Accurate serological assays are urgently needed to support public health responses to Zika virus (ZIKV) infection with its potential to cause foetal damage during pregnancy. Current flavivirus serology for ZIKVinfections lacks specificity due to cross-reacting antibodies from closely related other flaviviruses. In this study, we evaluated novel serological tests for accurate ZIKV IgG detection. METHODS: Our ELISAs are based on immune complex binding. The high specificity is achieved by the simultaneous incubation of labelled ZIKV antigen and unlabelled flavivirus homolog protein competitors. Two assays were validated with a panel of 406 human samples from PCR-confirmed ZIKVpatients collected in Brazil (n = 154), healthy blood donors and other infections from Brazil, Europe, Canada and Colombia (n = 252). RESULTS: The highest specificity (100% [252/252, 95% confidence interval (CI) 98.5-100.0]) was shown by the ZIKV ED3 ICB ELISA using the ED3 antigen of the ZIKV envelope. A similar test using the NS1 antigen (ZIKVNS1 ICB ELISA) was slightly less specific (92.1% [232/252, 95% CI 88.0-95.1]). The commercial Euroimmun ZIKV ELISA had a specificity of only 82.1% (207/252, 95% CI 76.8-86.7). Sensitivity was high (93-100%) from day 12 after onset of symptoms in all three tests. Seroprevalence of ZIKV IgG was analysed in 87 samples from Laos (Asia) confirming that the ED3 ELISA showed specific reactions in other populations. CONCLUSIONS: The novel ED3 ICB ELISA will be useful for ZIKV-specific IgG detection for seroepidemiological studies and serological diagnosis for case management in travellers and in countries where other flavivirus infections are co-circulating.
Authors: Christina Deschermeier; Christa Ehmen; Ronald von Possel; Carolin Murawski; Ben Rushton; John Amuasi; Nimako Sarpong; Oumou Maiga-Ascofaré; Raphael Rakotozandrindrainy; Danny Asogun; Yemisi Ighodalo; Lisa Oestereich; Sophie Duraffour; Meike Pahlmann; Petra Emmerich Journal: J Clin Microbiol Date: 2022-05-16 Impact factor: 11.677
Authors: Joshua J Anzinger; Chadwic D Mears; A E Ades; Keisha Francis; Yakima Phillips; Ynolde E Leys; Moira J Spyer; David Brown; Ana M Bispo de Filippis; Eleni Nastouli; Thomas Byrne; Heather Bailey; Paulette Palmer; Lenroy Bryan; Karen Webster-Kerr; Carlo Giaquinto; Claire Thorne; Celia D C Christie Journal: Emerg Infect Dis Date: 2022-02 Impact factor: 6.883